Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis.
Identifieur interne : 001657 ( PubMed/Checkpoint ); précédent : 001656; suivant : 001658Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis.
Auteurs : Pamela J. Hooper [États-Unis] ; Brian K. Chu [États-Unis] ; Alexei Mikhailov [Suisse] ; Eric A. Ottesen [États-Unis] ; Mark Bradley [Royaume-Uni]Source :
- PLoS neglected tropical diseases [ 1935-2735 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Filaricides.
- épidémiologie : Filariose lymphatique.
- Filariose lymphatique, Humains, Modèles biologiques, Modèles statistiques, Santé mondiale, Santé publique, Évaluation des risques.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Filaricides.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial.
- prevention & control : Elephantiasis, Filarial.
- Global Health, Humans, Models, Biological, Models, Statistical, Public Health, Risk Assessment.
Abstract
In 1997, the World Health Assembly adopted Resolution 50.29, committing to the elimination of lymphatic filariasis (LF) as a public health problem, subsequently targeted for 2020. The initial estimates were that 1.2 billion people were at-risk for LF infection globally. Now, 13 years after the Global Programme to Eliminate Lymphatic Filariasis (GPELF) began implementing mass drug administration (MDA) against LF in 2000-during which over 4.4 billion treatments have been distributed in 56 endemic countries-it is most appropriate to estimate the impact that the MDA has had on reducing the population at risk of LF.
DOI: 10.1371/journal.pntd.0003333
PubMed: 25411843
Affiliations:
- Royaume-Uni, Suisse, États-Unis
- Angleterre, District de Columbia, Grand Londres, Géorgie (États-Unis)
- Londres, Washington (district de Columbia)
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25411843Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis.</title><author><name sortKey="Hooper, Pamela J" sort="Hooper, Pamela J" uniqKey="Hooper P" first="Pamela J" last="Hooper">Pamela J. Hooper</name><affiliation wicri:level="2"><nlm:affiliation>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Chu, Brian K" sort="Chu, Brian K" uniqKey="Chu B" first="Brian K" last="Chu">Brian K. Chu</name><affiliation wicri:level="2"><nlm:affiliation>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Mikhailov, Alexei" sort="Mikhailov, Alexei" uniqKey="Mikhailov A" first="Alexei" last="Mikhailov">Alexei Mikhailov</name><affiliation wicri:level="1"><nlm:affiliation>Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Control of Neglected Tropical Diseases, World Health Organization, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Ottesen, Eric A" sort="Ottesen, Eric A" uniqKey="Ottesen E" first="Eric A" last="Ottesen">Eric A. Ottesen</name><affiliation wicri:level="3"><nlm:affiliation>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, United States of America; ENVISION Project, RTI International, Washington D.C., United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, United States of America; ENVISION Project, RTI International, Washington D.C.</wicri:regionArea><placeName><settlement type="city">Washington (district de Columbia)</settlement><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Bradley, Mark" sort="Bradley, Mark" uniqKey="Bradley M" first="Mark" last="Bradley">Mark Bradley</name><affiliation wicri:level="3"><nlm:affiliation>Global Health Programs, GlaxoSmithKline, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Global Health Programs, GlaxoSmithKline, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25411843</idno><idno type="pmid">25411843</idno><idno type="doi">10.1371/journal.pntd.0003333</idno><idno type="wicri:Area/PubMed/Corpus">001200</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001200</idno><idno type="wicri:Area/PubMed/Curation">001200</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001200</idno><idno type="wicri:Area/PubMed/Checkpoint">001200</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001200</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis.</title><author><name sortKey="Hooper, Pamela J" sort="Hooper, Pamela J" uniqKey="Hooper P" first="Pamela J" last="Hooper">Pamela J. Hooper</name><affiliation wicri:level="2"><nlm:affiliation>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Chu, Brian K" sort="Chu, Brian K" uniqKey="Chu B" first="Brian K" last="Chu">Brian K. Chu</name><affiliation wicri:level="2"><nlm:affiliation>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Mikhailov, Alexei" sort="Mikhailov, Alexei" uniqKey="Mikhailov A" first="Alexei" last="Mikhailov">Alexei Mikhailov</name><affiliation wicri:level="1"><nlm:affiliation>Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Control of Neglected Tropical Diseases, World Health Organization, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Ottesen, Eric A" sort="Ottesen, Eric A" uniqKey="Ottesen E" first="Eric A" last="Ottesen">Eric A. Ottesen</name><affiliation wicri:level="3"><nlm:affiliation>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, United States of America; ENVISION Project, RTI International, Washington D.C., United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, United States of America; ENVISION Project, RTI International, Washington D.C.</wicri:regionArea><placeName><settlement type="city">Washington (district de Columbia)</settlement><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Bradley, Mark" sort="Bradley, Mark" uniqKey="Bradley M" first="Mark" last="Bradley">Mark Bradley</name><affiliation wicri:level="3"><nlm:affiliation>Global Health Programs, GlaxoSmithKline, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Global Health Programs, GlaxoSmithKline, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><series><title level="j">PLoS neglected tropical diseases</title><idno type="eISSN">1935-2735</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Filaricides (therapeutic use)</term><term>Global Health</term><term>Humans</term><term>Models, Biological</term><term>Models, Statistical</term><term>Public Health</term><term>Risk Assessment</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (épidémiologie)</term><term>Humains</term><term>Modèles biologiques</term><term>Modèles statistiques</term><term>Santé mondiale</term><term>Santé publique</term><term>Évaluation des risques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Global Health</term><term>Humans</term><term>Models, Biological</term><term>Models, Statistical</term><term>Public Health</term><term>Risk Assessment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Filariose lymphatique</term><term>Humains</term><term>Modèles biologiques</term><term>Modèles statistiques</term><term>Santé mondiale</term><term>Santé publique</term><term>Évaluation des risques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In 1997, the World Health Assembly adopted Resolution 50.29, committing to the elimination of lymphatic filariasis (LF) as a public health problem, subsequently targeted for 2020. The initial estimates were that 1.2 billion people were at-risk for LF infection globally. Now, 13 years after the Global Programme to Eliminate Lymphatic Filariasis (GPELF) began implementing mass drug administration (MDA) against LF in 2000-during which over 4.4 billion treatments have been distributed in 56 endemic countries-it is most appropriate to estimate the impact that the MDA has had on reducing the population at risk of LF.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25411843</PMID><DateCreated><Year>2014</Year><Month>11</Month><Day>21</Day></DateCreated><DateCompleted><Year>2016</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis.</ArticleTitle><Pagination><MedlinePgn>e3333</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0003333</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In 1997, the World Health Assembly adopted Resolution 50.29, committing to the elimination of lymphatic filariasis (LF) as a public health problem, subsequently targeted for 2020. The initial estimates were that 1.2 billion people were at-risk for LF infection globally. Now, 13 years after the Global Programme to Eliminate Lymphatic Filariasis (GPELF) began implementing mass drug administration (MDA) against LF in 2000-during which over 4.4 billion treatments have been distributed in 56 endemic countries-it is most appropriate to estimate the impact that the MDA has had on reducing the population at risk of LF.</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">To assess GPELF progress in reducing the population at-risk for LF, we developed a model based on defining reductions in risk of infection among cohorts of treated populations following each round of MDA. The model estimates that the number of people currently at risk of infection decreased by 46% to 789 million through 2012.</AbstractText><AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">Important progress has been made in the global efforts to eliminate LF, but significant scale-up is required over the next 8 years to reach the 2020 elimination goal.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hooper</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Brian K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikhailov</LastName><ForeName>Alexei</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ottesen</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, United States of America; ENVISION Project, RTI International, Washington D.C., United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global Health Programs, GlaxoSmithKline, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>WHO_001</GrantID><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2001 May-Jun;95(3):336-41</RefSource><PMID Version="1">11491011</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Emerg Infect Dis. 2007 Apr;13(4):608-10</RefSource><PMID Version="1">17553278</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Wkly Epidemiol Rec. 2013 Sep 13;88(37):389-99</RefSource><PMID Version="1">24073461</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2000 Dec;5(12):848-54</RefSource><PMID Version="1">11169273</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitology. 1996 Apr;112 ( Pt 4):409-28</RefSource><PMID Version="1">8935952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2008;2(10):e317</RefSource><PMID Version="1">18841205</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>P N G Med J. 2000 Sep-Dec;43(3-4):172-82</RefSource><PMID Version="1">11939298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2010;4(6):e708</RefSource><PMID Version="1">20532228</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Trop Med Parasitol. 2002 Dec;96 Suppl 2:S15-40</RefSource><PMID Version="1">12630391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2002 Dec 5;347(23):1841-8</RefSource><PMID Version="1">12466508</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Trop Med Parasitol. 2005 Mar;99(2):155-64</RefSource><PMID Version="1">15814034</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Dis Poverty. 2013 Dec 02;2(1):30</RefSource><PMID Version="1">24289733</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2000 Sep;5(9):591-4</RefSource><PMID Version="1">11044272</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2006 Mar 25;367(9515):992-9</RefSource><PMID Version="1">16564361</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bull World Health Organ. 1992;70(6):769-76</RefSource><PMID Version="1">1486674</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4239000</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>06</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25411843</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0003333</ArticleId><ArticleId IdType="pii">PNTD-D-14-00965</ArticleId><ArticleId IdType="pmc">PMC4239000</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Angleterre</li><li>District de Columbia</li><li>Grand Londres</li><li>Géorgie (États-Unis)</li></region><settlement><li>Londres</li><li>Washington (district de Columbia)</li></settlement></list><tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Hooper, Pamela J" sort="Hooper, Pamela J" uniqKey="Hooper P" first="Pamela J" last="Hooper">Pamela J. Hooper</name></region><name sortKey="Chu, Brian K" sort="Chu, Brian K" uniqKey="Chu B" first="Brian K" last="Chu">Brian K. Chu</name><name sortKey="Ottesen, Eric A" sort="Ottesen, Eric A" uniqKey="Ottesen E" first="Eric A" last="Ottesen">Eric A. Ottesen</name></country><country name="Suisse"><noRegion><name sortKey="Mikhailov, Alexei" sort="Mikhailov, Alexei" uniqKey="Mikhailov A" first="Alexei" last="Mikhailov">Alexei Mikhailov</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Bradley, Mark" sort="Bradley, Mark" uniqKey="Bradley M" first="Mark" last="Bradley">Mark Bradley</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001657 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001657 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25411843
|texte= Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25411843" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |